Times of Oman
Price in RO
24ct / gm
22ct / gm
Forex Rates vs R01
Back to Homepage
Pfizer earnings dip on patent expirations, taxes
October 29, 2013 , 5 : 46 pm GST
SAVE THIS ARTICLE
A view of pharmaceutical company Pfizer Incorporated headquarters in New York. Photo - AFP
US pharmaceutical giant Pfizer Inc. on Tuesday reported a 19 per cent drop in earnings on lower revenues and higher taxes as it works to rebuild its product pipeline following patent expirations.
Net income came in at $2.6 billion revenues of $12.6 billion, down from $3.2 billion revenues of $13.0 billion in the year-ago period.
The results translated into earnings-per-share of 58 cents, excluding the effects of acquisitions and divestitures and special items, two cents above analyst forecasts. Revenues slightly lagged analyst projections of $12.7 billion.
Revenues from two of the company's blockbuster drugs, cholesterol drug Lipitor and sexual dysfunction drug Viagra, continued to erode in the quarter. The company's top two sellers are now Lyrica, which treats nerve and muscle pain, and the Prevnar line of vaccines.
Revenues for Lyrica rose 10 per cent, while revenue for Prevnar edged one per cent higher.
Pfizer chief executive Ian Read also pointed to strong gains from its anti-inflammatory drug
Celebrex and from new oncology products Inlyta and Xalkori.
"We continue to generate solid financial results on an operational basis, despite the impact of product losses of exclusivity" as well as "the challenging operating environment," Read said.
Read said the company was working on more than a half-dozen major product developments and joint ventures addressing type 2 diabetes, cancer pain and other ailments.
"Over the next several months, we expect to report key clinical data read-outs that will more clearly characterize the strength of our late-stage pipeline."
The profit decline compared with the year-ago period stemmed from lower revenues due in part to the loss of exclusivity of Lipitor drug, for which revenues fell from $749 million to $533 million, as well as to the positive impact in the 2012 period from favorable tax
settlements with the US and foreign countries.
The company incurred $985 million in taxes in the 2013 period compared with refunds of $183 million a year ago.
Earnings were also negatively affected by the spinoff of the Zoetis animal-care unit.
Pfizer trimmed its revenue forecast for the year from a range of $50.8-$52.8 billion previously to the current $50.8 billion-$51.8 billion. That's below the $51.45 billion forecast by analysts.
Per-share earnings are expected to come in at $2.15 - $2.20 versus the prior range of $2.10-$2.20. Analysts forecast $2.16 for the year.
Pfizer shares were down 0.5 per cent in pre-market trading.
Rate this Article
Rates : 0, Average : 0
Post a Comment
Did you like this section? Leave a comment!
Your Name :
Your Email Address :
Your Comment :
Enter ImageText here:
No Comments Posted
Latest in this section
US lawmakers announce two-year budget deal
Japan to spend $970 mn on nuclear soil store: report
GCC firms eye Occidental’s stake in Mena region
Experts to deliberate on STP at workshop
MSM index ends lower amid Al Madina Takaful debut
TOP RATED ARTICLES
World leaders, South Africans say rainy, raucous farewell to Mandela
Embarrassed to ‘overtake Viv’
Clarke aims for Ashes, top ranking
Arjun Kapoor's next film to be titled 'Tevar'
Ronaldo, Messi, Ribery shortlisted
More in News
How to choose your writing form and communicate your creative thoughts
Natasja Engholm - Special to Times of Oman
Indonesia's illegal dentists bite back after ban
Albanian cannabis fiefdom at heart of European traffic
Asia's animators draw inspiration from Miyazaki
Splash 'Forever More'
Times News Service
More in Features
Musharraf is ready for trial, but is the government?
Of Middle East and the Arab winter
France ill at ease with US policy shift in M-E
The harsh reality of mass migration from Syria
Blind obsession with celebrities
Jayanta G Borpujari
More in Columns
Get Top news by E-mail.
Copyright © 2012 Muscat Press & Publishing House SAOC. All rights reserved. Times of Oman is not responsible for the content of external internet sites.
For reprint rights contact:
TOO Online Editorial